AstraZeneca profit up on strong sales of cancer drugs

AstraZeneca profit up on strong sales of cancer drugs

Profit after tax climbed more than one fifth compared with the first quarter last year to $2.18 billion, AstraZeneca said in a results statement.

"AstraZeneca had a very strong start in 2024," chief executive Pascal Soriot said in the statement, which noted a 26-percent increase in revenue from oncology treatments.

Total group sales increased 19 percent to $12.7 billion in the first quarter.

"Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer," added Soriot.

AstraZeneca's share price jumped 5.7 percent to £120 following the update.

"Cancer treatment sales remain buoyant, generating two-fifths of overall revenues in this latest quarter," noted Keith Bowman, equity analyst at Interactive Investor.

"Astra continues to win new drug approvals, sales on a geographical basis are diverse including growing sales in China, while takeovers such as its 2021 purchase of rare disease focused Alexion have expanded its diversity of drug treatments."

The first quarter saw the company agree to buy US biopharma firm Fusion for up to $2.4 billion, in its latest expansion into cancer treatments.

Fusion is developing next-generation radiotherapy to treat cancer via precise targeting that minimises damage to healthy cells.

AstraZeneca's latest push into oncology comes after its net profit almost doubled to $6 billion last year as a strong cancer division helped offset a wipeout for sales of its Covid treatments.

Also in the first quarter, the group struck a deal to purchase French biotech specialist Amolyt Pharma for about $1 billion, bolstering its rare diseases division Alexion.

AstraZeneca Vietnam dedicated to health AstraZeneca Vietnam has started the year by building on last year’s success with programmes that cater to improving livelihoods and enhancing healthcare.

AstraZeneca buys French biotech firm Amolyt for $1 bn Anglo-Swedish pharmaceuticals giant AstraZeneca on Thursday agreed to buy French biotech specialist Amolyt Pharma for about $1 billion, expanding further into the field of rare drugs.

Vietnam Minister of Planning and Investment visits AstraZeneca China A Vietnamese delegation led by Minister for Planning and Investment Nguyen Chi Dung on March 30 visited AstraZeneca Global (R&D) China Centre and the Shanghai Jing'an CCiC & iCampus.